Artificial Intelligence-Driven Design of Antisense Oligonucleotides for Precision Medicine in Neuromuscular Disorders
Preprint
- 18 September 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Rare neuromuscular disorders impose a significant burden on patients, caregivers, and the health care system. However, effective disease-modifying therapies remain limited. Antisense oligonucleotides (ASOs) have emerged as a promising therapeutic strategy, en-abling targeted modulation of gene expression through mechanisms such as exon skip-ping, exon inclusion, and transcript degradation. Despite the clinical approval of several ASO therapies, their efficacy is often limited by challenges such as poor target tissue up-take and delivery constraints, highlighting the need for improved design strategies. Recent advances in machine learning have led to the development of ASO optimization plat-forms such as eSkipFinder and ASOptimizer, which aim to predict effective ASO se-quences and chemistries for specific RNA targets. While these tools show considerable promise, their broader applicability remains limited due to a lack of comprehensive vali-dation and the absence of integrated safety considerations. Further refinement and valida-tion are necessary to improve their translational utility. Nevertheless, these platforms rep-resent a critical advancement in accelerating ASO development. By improving design pre-cision, reducing reliance on extensive preclinical screening, and allowing researchers with minimal experience in their design to have confidence in the platform’s outputs, machine learning is likely to enhance the accessibility and efficiency of ASO therapy for rare neu-romuscular disorders.Keywords
All Related Versions
- Version 1, 2025-09-18, Preprints
- Published version: Genes, 16 (12), 1468.
This publication has 192 references indexed in Scilit:
- Challenges and Possible Strategies to Address Them in Rare Disease Drug Development: A Statistical PerspectiveClinical Pharmacology & Therapeutics, 2025
- Synthesis of 7’‐Substituted 2’‐O‐4’‐C‐Ethylene Bridged Nucleic Acid (ENA)‐Thymidine MonomersEuropean Journal of Organic Chemistry, 2023
- Eplontersen for Hereditary Transthyretin Amyloidosis With PolyneuropathyJAMA, 2023
- Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double‐blind, placebo‐controlled, dose‐titration trialMuscle & Nerve, 2021
- Opportunities and challenges for antisense oligonucleotide therapiesJournal of Inherited Metabolic Disease, 2020
- The powerful world of antisense oligonucleotides: From bench to bedsideWIREs RNA, 2020
- Eteplirsen for the treatment of Duchenne muscular dystrophyAnnals of Neurology, 2013
- Efficacy of systemic morpholino exon‐skipping in duchenne dystrophy dogsAnnals of Neurology, 2009
- Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutationsHuman Mutation, 2009
- Time course of changes in plasma membrane permeability in the dystrophin‐deficient mdx mouseMuscle & Nerve, 1994